Clinical Trial Details
| Trial ID: | L7115 |
| Source ID: | NCT00817505 |
| Associated Drug: | Azd1656 |
| Title: | To Evaluate the Bioavailability of a Tablet of AZD1656 |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Type 1 Diabetes |
| Interventions: | DRUG: AZD1656|DRUG: AZD1656 |
| Outcome Measures: | Primary: Pharmacokinetic variables ( Area under the plasma concentration vs. time curve (AUC), maximum plasma concentration (Cmax), time to reach maximum plasma concentration (tmax), terminal elimination half-life (t½) and apparent oral clearance (CL/F), Blood samples taken up to 72 hours | Secondary: Pharmacodynamic variables (Plasma glucose), Taken repeatedly during treatment periods|Safety Variables (AEs, BP, pulse, electrocardiogram (ECG), hypoglycaemic symptoms and laboratory variables), Taken during treatment periods |
| Sponsor/Collaborators: | Sponsor: AstraZeneca |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE1 |
| Enrollment: | 11 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2008-12 |
| Completion Date: | 2009-09 |
| Results First Posted: | |
| Last Update Posted: | 2009-11-03 |
| Locations: | Research site, San Antonio, Texas, United States |
| URL: | https://clinicaltrials.gov/show/NCT00817505 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|